| Bernardi et al.9, 2012 |
17 (n = 225 participants) |
Nine trials comparing albumin with other volume expanders formed the leading category, i.e. 74% (903 of 1,225) of all patients in the meta-analysis, compared with 13% each for trials with no treatment or vasoconstrictor as the control regimen. |
Albumin remains superior to other treatment modalities, and further added that the combination of vasoconstrictor with albumin would further decrease the incidence of PICD, which has not been investigated to date. |
| Kwok et al.51, 2013 |
16 (n = 1518 participants) |
Four studies with no active comparator, and eight studies comparing plasma expander to albumin, and four other studies of cirrhotic patients with infection compared the use of antibiotics with and without albumin |
Albumin use significantly reduced risk of paracentesis-induced circulatory dysfunction, but there was a nonsignificant difference in complications and mortality. |
| Simonetti et al.52, 2019 |
27 (n = 1592 participants) |
Five of the trials assessed plasma expanders (albumin in four trials and ascitic fluid in one trial) versus no plasma expander. The remaining 22 trials assessed one type of plasma expander, i.e. dextran, hydroxyethyl starch, polygeline, intravenous infusion of ascitic fluid, crystalloids, or mannitol versus another type of plasma expander, i.e. albumin in 20 of these trials and polygeline in one trial. |
There was neither any benefit nor any adverse effect in using any plasma expanders including albumin, polygeline, dextrans, hydroxyethyl starch, intravenous infusion of ascitic fluid, and crystalloids in patients undergoing paracentesis. |
